Brief: Advicenne Receives Positive CHMP Opinion Recommending Approval Of ADV7103 (Sibnayal®)

Advicenne SA

10/12/2020 17:14

Dec 10 (Reuters) - ADVICENNE SA  ADVIC.PA :
    * ADVICENNE RECEIVES POSITIVE CHMP OPINION RECOMMENDING
APPROVAL
OF ADV7103 (SIBNAYAL®) FOR THE TREATMENT OF DISTAL RENAL TUBULAR
ACIDOSIS (DRTA)
    * A FINAL DECISION ON MARKETING AUTHORISATION OF ADV7103 IN
EUROPEAN UNION IS EXPECTED IN COMING WEEKS/MONTHS
    * IN ORDER TO MAKE ADV7103 QUICKLY AND BROADLY AVAILABLE IN
ALL EU
COUNTRIES, ADVICENNE HAS DECIDED TO SET UP PARTNERSHIPS WITH
SPECIALIZED DISTRIBUTORS
    * THIS APPROACH WILL ALLOW ADVICENNE TO ALLOCATE ITS
RESOURCES ON
CLINICAL DEVELOPMENT OF ADV7103 IN UNITED STATES

Source text for Eikon:  ID:nBw2Pjt3za 
Further company coverage:  ADVIC.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))